- Home
- IMTX vs FDUS Comparison
IMTX vs FDUS Comparison
Compare IMTX & FDUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMTX
- FDUS
- Stock Information
- Founded
- IMTX N/A
- FDUS 2011
- Country
- IMTX Germany
- FDUS United States
- Employees
- IMTX N/A
- FDUS N/A
- Industry
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- FDUS Finance/Investors Services
- Sector
- IMTX Health Care
- FDUS Finance
- Exchange
- IMTX Nasdaq
- FDUS Nasdaq
- Market Cap
- IMTX 579.8M
- FDUS 654.0M
- IPO Year
- IMTX N/A
- FDUS 2011
- Fundamental
- Price
- IMTX $5.71
- FDUS $20.78
- Analyst Decision
- IMTX Strong Buy
- FDUS Hold
- Analyst Count
- IMTX 4
- FDUS 1
- Target Price
- IMTX $14.67
- FDUS $20.00
- AVG Volume (30 Days)
- IMTX 773.0K
- FDUS 205.5K
- Earning Date
- IMTX 08-12-2025
- FDUS 07-31-2025
- Dividend Yield
- IMTX N/A
- FDUS 10.88%
- EPS Growth
- IMTX N/A
- FDUS N/A
- EPS
- IMTX N/A
- FDUS 2.33
- Revenue
- IMTX $155,801,989.00
- FDUS $147,999,000.00
- Revenue This Year
- IMTX N/A
- FDUS $4.94
- Revenue Next Year
- IMTX $1.92
- FDUS $6.51
- P/E Ratio
- IMTX N/A
- FDUS $8.92
- Revenue Growth
- IMTX 93.56
- FDUS 9.06
- 52 Week Low
- IMTX $3.30
- FDUS $16.70
- 52 Week High
- IMTX $13.09
- FDUS $23.55
- Technical
- Relative Strength Index (RSI)
- IMTX 55.46
- FDUS 64.45
- Support Level
- IMTX $5.23
- FDUS $19.77
- Resistance Level
- IMTX $5.82
- FDUS $20.07
- Average True Range (ATR)
- IMTX 0.28
- FDUS 0.30
- MACD
- IMTX -0.05
- FDUS 0.07
- Stochastic Oscillator
- IMTX 43.48
- FDUS 98.57
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.
About FDUS Fidus Investment Corporation
Fidus Investment Corp is an externally managed, closed-end, non-diversified management investment company that has elected to be treated as a business development company. The company provides customized debt and equity financing solutions to lower middle-market companies. Its investment objective is to provide attractive risk-adjusted returns by generating both current income from debt investments and capital appreciation from equity related investments. The company's portfolio of investments is comprised of securities of companies from different industries such as, Information Technology Services, Business Services, Healthcare Products among others.